CrossrefInfokarte
Correction to: Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
The Oncologist · 2026-11-05 · 31 (12)
DOI: 10.1093/oncolo/oyag418 ↗Abstract
Kein Abstract verfügbar.
EUVIMED